Drugs for immunological or allergic disorders (A61P37)

A   Human necessities(308424)
A61P37                 Drugs for immunological or allergic disorders(1768)

Salts and crystalline forms of apottosis-inducing agent // 2628560
FIELD: pharmacology.SUBSTANCE: invention relates to a compound having the systematic name 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy) benzamide (compound 1) in the form of a free base crystalline anhydrate, a free base hydrate of crystalline form, a solvate of crystalline form, a hydrochloride salt of crystalline form, or a sulfate salt of crystalline form. The invention also relates to a pharmaceutical composition having an inhibitory activity against anti-apoptotic proteins of the Bcl-2 family comprising a therapeutically effective amount of the compound of the invention and one or more pharmaceutically acceptable excipients.EFFECT: crystalline forms of compound 1 suitable for use as an active pharmaceutical ingredient.21 cl, 14 dwg, 14 tbl, 17 ex
Tricyclic nitrogen-containing derivatives of imidazo[4,5-c]pyridine, having inhibiting activity in response to hystamine 4 receptor (hh4r) // 2628074
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of formula 1 , or to a racemate, isomer, or pharmaceutically acceptable salt thereof, wherein X1 and X2 are C; each of X3 and X4 is independently C or N, provided that one of X3 and X4 is N; R1 is a saturated 4-9 member mono- or bi-heterocyclyl containing 1-2 heteroatoms (where the heteroatoms are N), where R1 is unsubstituted or substituted by 1 to 3 substituents selected from -NR6R7 and R8; or R1 is selected from -NR6R7 and R8; R2, R3, R4 and R5 may be the same or different; and each is independently selected from -H; -C1-C6alkyl; -C1-C6haloalkyl; -C1 -C6perhaloalkyl; -halogen (-F, -Cl, -Br, -I); -CN; -C1-C6talkoxy; -C1-C6haloalkoxy; -C1-C6perhaloalkoxy; C2alkenyl; -C2-C3alkynyl; -amino; -OH; -nitro (-NO2); -C6-C1aryl; and furan; provided that, when X3 is N, R4 is absent; and when X4 is N, R5 is absent, each of Y1, Y2, Y3, Y4 and Y5 is independently C or a heteroatom (preferably a heteroatom independently selected from N, O and S), provided that at least two of Y1, Y2, Y3, Y4 and Y5 are heteroatoms independently selected from N and O; each of Y2 and Y3 can be independently substituted by R9; Y4 may be substituted with -H or -C1-C6alkyl; each of R6 and R7 is independently selected from -H; -C1-C6alkyl; and -carboxyl (-COOH); R8 is -C1-C6alkyl or -C3cycloalkyl; and R9 is selected from -H; -C1-C6alkyl; and -C3cycloalkyl; wherein the alkyl and heterocyclyl may be independently unsubstituted or substituted by one or more substituents (for example, 1 to 3 substituents) selected from the group consisting of -C1-C4alkyl, -C1-C4alkoxy and -OH. The invention also relates to particular compounds and a pharmaceutical composition based on the said compounds.EFFECT: new heterocyclic compounds useful for human histamine receptor 4 inhibition are obtained.13 cl, 13 tbl, 144 ex
Compounds of pyridazinamide and their use as synthetic syneckinasis inhibitors (syk) // 2627661
FIELD: chemistry.SUBSTANCE: invention relates to novel pyridazinamides of the formula I , where all variable substituents are defined in the claims, and their pharmaceutically acceptable salts, as well as a pharmaceutical composition based on them.EFFECT: compounds of the formula are SYK inhibitors and are useful for the treatment of autoimmune and inflammatory diseases.10 cl, 1 tbl, 43 ex
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl
ethod of treatment of epithelial pilonidal sinus at the stage of abscedation // 2627350
FIELD: medicine.SUBSTANCE: after excision of the epithelial pilonidal sinus with the abscess shells, the wound bottom is treated for 5 minutes with a gas stream containing the nitrogen monoxide of the Plazon apparatus in the NO-therapy regime. After suturing and vacuum drainage of the wound along the Redon, deviating from the left and right edges of the ends of the postoperative wound, is administered subcutaneously in a solution of 32 units of lidase. 10 minutes after the administration of lidase, retreating to 1 cm from the place of its introduction, injected subcutaneously in a solution of 50 mcg of immunophane. The administration of lidase and immunofan is repeated after 48 hours in combination with the treatment of the postoperative wound for 5 minutes with nitrogen monoxide in the NO-therapy regimen.EFFECT: method allows to improve the results of treatment of patients with epithelial coccygeal circulation at the stage of abscess formation, due to the combined and complex effect on the wound and its area.3 dwg, 1 ex
Aza-aryl-1-h-pyrazol-1-yl-sulphonamides // 2627268
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) ,in which radicals and characters have values specified in the claims and their versions. The proposed compounds act as potent antagonists of CCR (9) receptor. Animal testing has shown that these compounds are useful for treatment of inflammation, disease with a hallmark for CCR (9). The compounds as a whole are arylsulfamide derivatives and are used in pharmaceutical compositions, methods for treatment of CCR (9) mediated diseases and as a control in assays for identification of CCR (9) antagonists.EFFECT: increased efficiency of compounds application.26 cl, 2 tbl, 33 ex

1-phenyl-2-pyridinylalkyl alcohols derivatives as phosphodiesterase inhibitors // 2626956
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of general formula , where: R1 is selected from the group consisting of: methyl; trifluoromethyl; R2 is selected from the group consisting of: methyl optionally substituted with cyclopropyl; cyclopentyl; or R1 and R2, together with their interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (q) condensed with a phenyl group that carries -OR1 and -OR2 groups, where the asterisks indicate carbon atoms shared by such phenyl ring: , R19 is hydrogen; R3 is one or more substituents independently selected from halogen atoms; Z represents a -(CH2)n- group, where n is 0 or 1; A is a saturated and monocyclic (C3-C7) heterocycloalkylene group selected from the following list of di-radicals: , , , , , , , , , , where symbols [3] and [4] indicate the points of group A attachment to groups Z and K, respectively; K is selected from the group consisting of: -(CH2)mC(O)R4, where m can be 0 or 1; -C(O)(CH2)jR4, where j can be 1 or 2; -SO2(CH2)pR4, where p can be 0, 1 or 2; -(CH2)ySO2R4, where y can be 1 or 2; -(CH2)zR4, where z can be 1; and -C(O)(CH2)2SO2R4; R4 is a ring system which is a mono- or bicyclic ring which may be saturated, partially unsaturated or fully unsaturated, selected from phenyl, (C3-C8) cycloalkyl, (C3-C7) heterocycloalkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH and O or heteroaryl, such ring is optionally substituted with one or more R5, which may be the same or different and which are independently selected from the group consisting of: (C1-C6) alkyl, optionally substituted with one or more groups independently selected from the list consisting of: -OH; (C3-C7) heterocycloalkyl(C1-C4)alkyl where at least one ring carbon atom is replaced by a heteroatom selected from N, NH, O; 5-6 member heteroaryl where at least one ring carbon atom is replaced by a heteroatom selected from N and O; -OR6 group, where R6 is selected from the group consisting of (C1-C6) haloalkyl; -SO2R7 group, where R7 is (C1-C4) alkyl; and methyl optionally substituted with one or more (C3-C7) cycloalkyls; halogen atoms; CN; NR8R9, where R8 and R9 are different or identical and independently selected from the group consisting of: H; (C1-C4) alkylen-NR13 R14, where R13 and R14 are different or identical and independently selected from the group consisting of: a (C1-C6) alkyl, or they form a saturated (C3-C7) heterocyclic ring together with the nitrogen atom to which they are attached; -SO2R15 group, where R15 is selected from the group consisting of: (C1-C4) alkyl; -C(O)OR17 group, where R17 is selected from the group consisting of: (C1-C6) alkyl; or they form, together with the nitrogen atom to which they are attached, a saturated or partially saturated heterocyclic ring which is optionally substituted by one or more (C1-C6) alkyl; (C1-C2) alkylene-NR8R9, as mentioned above; COR10, where R10 is (C1-C6) alkyl; oxo; -SO2R11, where R11 is (C1-C4) alkyl or NR8R9, where R8 and R9 are as above; -COOR12, where R12 is H, (C1-C4) alkyl or (C1-C4) alkylene-NR8R9, where R8 and R9 are as above; and -CONR8R9, where R8 and R9 are as above; where R6, R8, R9, R10, R11, R12, R13, R14, R15, R17 and R19 groups in each case may have the same or different value if more than one group is present; and their N-oxide derivatives on the pyridine ring or their pharmaceutically acceptable salts. The compound is a phosphodiesterase 4 (PDE4) enzyme inhibitors.EFFECT: improved properties.19 cl, 26 tbl, 36 ex
2-[6-methyl-4-(tietane-3-yloxy)pyrimidine-2-ylthio] acetic acid methylidenhydrazide with antioxidant activity // 2626651
FIELD: pharmacology.SUBSTANCE: invention relates to a new compound of -(5-bromo-2-hydroxyphenyl)methylidenehydrazide of 2-[6-methyl-4-(thietane-3-yloxy)pyrimidin-2-ylthio]acetic acid of formula I .EFFECT: compound has antioxidant activity and stimulating protective activity of phagocytes.3 cl, 4 tbl, 4 ex

Peptides obtained from p16ink4a for prevention and treatment of hpv-associated tumours and other tumours expressing p16ink4a // 2626542
FIELD: biotechnology.SUBSTANCE: invention is a fragment of a cyclin-dependent p16INK4a kinase inhibitor, capable of inducing an immune response against p16INK4a, a nucleic acid molecule, a vector containing a nucleic acid molecule, a viral vector, as well as their use.EFFECT: invention allows to increase secretion of interferon-gamma T-cells or induce T-cell proliferation, and use these fragments to immunize an individual against HPV-associated or other types of cancer expressing pl6INK4a, preferably for the advanced types of cancer.15 cl, 5 dwg, 1 tbl, 5 ex
Connections of substituted triazolbronic acid // 2625801
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I): , wherein the residues R1, R1' and R1ʺ independently represent hydrogen, alkoxy, halogen or -CF3 group. The residue R2 it represents C1-7alkyl or phenyl, or a pharmaceutically acceptable salt thereof. Also pharmaceutical composition, using the compounds of formula I, and method of treatment are provided.EFFECT: compounds of formula I are inhibitors immunoproteasomal subunit LMP7, and may be useful in the treatment of inflammatory diseases and disorders such as rheumatoid arthritis, lupus and irritable bowel syndrome.13 cl, 1 tbl, 5 ex
ethod for prevention of exacerbation of bronchial asthma and chronic obstructive pulmonary disease // 2625744
FIELD: medicine.SUBSTANCE: invention is intended for prevention of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) exacerbations. Against the background of basic therapy, interferon inducer Tiloron is prescribed according to the following scheme: 1st year - 1st day - 250 mg once, 2nd day - 125 mg once and then 2 days later 125 mg once, 1.25 per course; for the 2nd year the course is repeated in the preseason ARVI period: 1st day - 250 mg, 2nd - 125 mg and then 2 days later 125 mg once, 750 mg per course.EFFECT: decreased severity and frequency of infectious exacerbations of bronchial asthma and chronic obstructive pulmonary disease and prolongation of remission time.2 cl, 6 tbl, 1 ex

Cationic emulsions "oil-in-water" // 2625546
FIELD: medicine.SUBSTANCE: composition comprising a self-replicating RNA molecule encoding an antigen in combination with a cationic oil-in-water emulsion particle is provided, wherein the particle contains an oil core and a cationic lipid and wherein the average particle diameter of the emulsion particles is from about 80 to 180 nm. Method for preparing the above composition, methods for eliciting an immune response in an individual, and using a composition for eliciting an immune response are provided.EFFECT: stable compositions suitable for the delivery of RNA molecules encoding an antigen into cells and the preparation of vaccines based on such molecules.35 cl, 14 dwg, 31 tbl, 9 ex

Hypoallergenic variants of mal d 1, main malus domectica allergen // 2624030
FIELD: biotechnology.SUBSTANCE: aprotein is produced. It is a hypoallergenic mutant of the main Malus domectica Mal d 1 allergen TCD having SEQ ID NO: 1 for the use in immune therapy of patients allergic to Malus domectica and/or Betula verrucosa pollen. The resulting protein has an amino acid sequence. When the SEQ ID NO: 1 is aligned in it, there are either two substitutions, including the Asp residue substitution at position 25 and the Asn residue substitution at position 78, or one Asn residue substitution at position 78 of the sequence SEQ ID NO: 1, where these residues of Asp at position 25 and/or of Asn at position 78 are substituted by Ala residue. The invention allows producing a hypoallergenic mutant of the main Malus domectica Mal d 1 allergen which shows a reduced IgE reactivity compared to the specified Mal d 1 allergen with SEQ ID NO: 1.EFFECT: possibility of using in medicine for the treatment of allergic diseases.14 cl, 15 dwg, 3 tbl, 13 ex
ethod for complex treatment of infectious acute optical neuritis // 2623870
FIELD: medicine.SUBSTANCE: to treat infectious acute optical neuritis, retrobulbar infusions of dexamethasone and emoxipin are performed for 10 days via an irrigation system. Simultaneously, three immunomodulating preparations are used: 6 mg of polyoxidonium dissolved in 200.0 ml of physiological solution are injected intravenously every day; endonasal electrophoresis with 0.25% derinat solution at a current strength of 0.5-1 mA for 8 to 10 minutes; 2 ml of 12.5% of cycloferon are injected intramuscularly according to the scheme: the first 2 days - daily, the next 3 injections - every other day and the remaining 5 injections - every 3 days.EFFECT: use of the invention allows to restore the antibacterial and antiviral functions of the immune system, normalize the mechanisms of antioxidant protection, neuro-trophic activity, prevent the negative effects of GCS therapy, shorten the periods of inflammatory reaction arrest in the optic nerve and restore visual functions.2 ex
Biologically active food additive // 2623152
FIELD: pharmacology.SUBSTANCE: invention can be used to create biologically active therapeutic and prophylactic compositions containing dry and liquid extracts of medicinal plants, functional foods that increase body immunobiological resistance and have hepatoprotective effect. A composition having hepatoprotective immunostimulating properties comprises modified dextran and a physiologically acceptable excipient. Dextranal with a molecular weight of 20-75 kDa is used as the modified dextran at a certain ratio of components.EFFECT: composition has a more effective hepatoprotective and immunostimulating activity and can be manufactured in any technologically acceptable form.4 cl, 1 tbl, 6 ex
ethod for human immunity improvment and composition for its implementation // 2622994
FIELD: medicine.SUBSTANCE: method involves inhalation of air enriched with biologically active essential oil solutions sprayed indoors to a concentration of 0.05-0.25 mg/m3. This essential oil contains readily volatile monoterpenes and semi-volatile sesquiterpenes and is obtained by exhaustive hydroparastillation of plant raw materials with water. Essential oil of siberian pine (cedar) containing at least 160 terpenoids or siberian pine (cedar) containing at least 160 terpenoids and siberian fir, containing at least 70 components, taken in the ratio of 1:1, or siberian pine (cedar), containing at least 160 terpenoids, siberian fir, containing at least 70 components, and marsh aura root, containing at least 100 components, taken in the ratio of 1:1:0.1. Also the invention relates to compositions containing the specified essential oil in the amount of 2.5-10% and 95-96% aqueous solution of ethyl alcohol in an amount of 90.0-97.5 wt %.EFFECT: increased immunity and improved intestinal microflora.2 cl, 3 tbl, 3 ex
ethod of producing preparation for implementation of biological potential of farm animals // 2622981
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary science and is intended for increasing non-specific body resistance in pigs. 90 wt of 0.2–0.3 % agar suspension is mixed with and 2.5 wt% of concentrated purified polysaccharide complex of yeast cells. To obtained mixture with constant stirring following things are added: 3.5 wt% of benzimidazole derivative (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazole hydrochloride, 5.0 million UN of I generation cephalosporin antibiotic – cefazolin, and 0.2 wt% of formalin, volume is brought to 100 wt%.EFFECT: invention is highly effective for increasing non-specific body resistance in pigs.1 cl, 5 tbl, 4 ex
ethod of producing preparation for implementation of reproductive properties of cows and productive potential of calves // 2622765
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary science and is intended for activation of non-specific body resistance in cattle. 90 wt% of 0.2–0.3 % agar suspension is mixed with 2.5 wt% of concentrated purified polysaccharide complex. To obtained mixture with constant stirring following things are added 3.5 wt% of (-)2,3,5,6-tetrahydro-6-phenylimidazo-[2,1-b]-thiazol hydrochloride, 5.0 million UN of antibiotic amikacine and 0.2 wt% of formalin, volume is brought to 100 wt%.EFFECT: invention is highly effective for activation of non-specific body resistance in cattle.1 cl, 4 tbl, 5 ex

Selective and reversible ubiquitin-specific protease 7 inhibitor // 2622640
FIELD: pharmacology.SUBSTANCE: viral infections and diseases are selected from viral infections of Herpes simplex-1 or -2, hepatitis A, hepatitis C, SARS of coronavirus infection and disease, Epstein-Barr virus, rhinovirus infections and diseases, adenovirus infections and diseases, poliomyelitis. In the formula each identical or different R1 is selected from the group consisting of halogen, linear or branched (C1-C6)alkyl, OR; L1 is a linear or branched (C1-C6)alkylene; Q is 0, 1, 2, 3 or 4; X' is CR7; R7 is OR; N is 0, 1 or 2; P is 1, 2 or 3; R3, R4, R8' and R8 each represents H; A is -C (O)-; L2 is linear or branched (C1-C6) alkylene, optionally interrupted by at least one O; R6 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, H, wherein aryl, heteroaryl, cycloalkyl is mono- or polycyclic and is optionally substituted by halogen, OR; each R, identical or different, is independently selected from H, linear or branched (C1-C6)alkyl. At that, "aryl" means an aromatic monocyclic hydrocarbon ring system of 6 carbon atoms, "cycloalkyl" means a non-aromatic, monocyclic, hydrocarbon ring of 3-10 carbon atoms; "heteroaryl" means a 5-membered aromatic mono-heterocyclic ring. The invention also relates to versions of the for preparation of compounds.EFFECT: compounds can be used to prepare a drug for treatment or prevention of cancer and metastases, viral infections and diseases, or viral infectivity, or latency mediated by ubiquitin-specific proteases activity.19 cl, 6 dwg, 4 tbl, 14 ex

Compound 8-fluorophthalazine-1(2h)-one as inhibitors of bruton tyrosine kinase // 2622391
FIELD: pharmacology.SUBSTANCE: compounds of 8-fluorophthalazine-1(2H)-ones of formula II are proposed, wherein one of X1, X2 and X3 represent N, and the other symbols have meanings defined in claim 1 of the invention formula, or stereoisomers, gautomers and pharmaceutically acceptable salts thereof. The compounds proposed inhibit the kinase Btk (Bruton tyrosine kinase) and can be used to treat immune disorders, such as inflammation, mediated by kinase Btk.EFFECT: increased efficiency while using the compounds of formula II for the diagnosis and treatment in vitro, in situ and in vivo such disorders in mammalian cells, or associated pathological conditions.25 cl, 8 dwg, 2 tbl, 69 ex

Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility // 2622024
FIELD: medicine.SUBSTANCE: effective treatment method represents a complex therapy that includes enzyme therapy, physical therapy, hormone therapy, as well as application of liposomal dihydroquercetin emulsion "Flamena".EFFECT: application of the method allows to achieve pregnancy for more than 90 percent of patients.3 cl, 3 dwg, 3 tbl, 3 ex
ethods of obtaining molecular structures containing antigenic epitopes of topical allergens and signal peptides with immunoregulatory properties // 2622004
FIELD: biotechnology.SUBSTANCE: method for obtaining molecular structures with immunoregulatory properties containing antigenic epitopes of topical allergens and an ornithine decarboxylase signal peptide (ODCsig) is proposed. The gene encoding the protein-allergen by cloning is obtained, the ODCsig sequences are selected, the DNA sequences encoding the ODCsig signal peptides are cloned, the chimeric gene and the DNA constructs are developed to express the chimeric protein-allergens in bacterial cells.EFFECT: invention provides specific immunotherapy for patients with allergies.10 dwg, 2 tbl, 15 ex
Composition for stimulation of nonspecific resistance and metabolism of broiler chicks // 2621999
FIELD: veterinary medicine.SUBSTANCE: includes levamisole as immunomodulator, amber acid as a biologically active compound, water soluble salts of iron, copper, zinc, cobalt and water at the following component ratio, wt %: levamisole - 0.75, amber acid - 1.0, ferrous sulfate - 2.0, copper sulfate - 0.2, zinc sulphate - 0.6, cobalt sulfate - 2.0, distilled water - rest. The method includes the use of the claimed composition. The composition dissolved in water as 1:3 is to be given to chickens in the following age periods, days: 5-6; 12-14; 16-18; 20-22; 24-26; 27-35.EFFECT: increase nonspecific resistance and metabolism of meat chickens.2 cl, 4 tbl, 2 ex

Antibody agains csf-1r // 2621859
FIELD: biotechnology.SUBSTANCE: proposed allocated recombinant or purified antibody that specifically binds to the receptor of colony stimulating factor-1 (CSF-1R, CSF-1R), characterized by amino acid sequences of the variable domains. Also is provided nucleic acid encoding the antibody of the invention, vector, cell and method of producing the antibody. Furthermore, a pharmaceutical composition and the use of the antibodies and pharmaceutical composition of the invention as a medicament for the treatment of cancer, disease associated with increased osteoclast activity, inflammatory disease and rheumatoid arthritis, are described.EFFECT: invention may find further application in the treatment of diseases associated with the CSF-1R.19 cl, 32 dwg, 4 tbl

Treatment method // 2621148
FIELD: medicine.SUBSTANCE: group of inventions is intended for treatment of inflammatory immune diseases mediated by T-cells, or of allergic diseases mediated by T-cells. The patient in need of treatment receives an effective amount of N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide or a pharmaceutically acceptable salt thereof.EFFECT: group of inventions allows to provide higher clinical effectiveness.8 cl, 3 dwg, 1 tbl, 373 ex

Content for stimulating metabolic processes, immune system, prevention the diseases and diarrhea // 2620554
FIELD: veterinary medicine.SUBSTANCE: declared composition has metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases with diarrhea syndrome, comprising succinic acid and SDA iodinol second fraction with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml of SDA second fraction - 40 ml. The following is also claimed: composition having metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases diarrhea syndrome comprising succinic acid, iodinol, levamisole with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml , levamisole - 10.0 g.EFFECT: stimulation of metabolism and the immune system, prevention of gastrointestinal diseases, and increase the activity of the growth of young farm animals.2 cl, 6 tbl, 3 ex

odified peptides and their application for treatment of autoimmune diseases // 2620070
FIELD: medicine, pharmacy.SUBSTANCE: this invention relates to the field of biotechnology, particularly to an immunosuppressive agent, and can be used for the treatment of systemic lupus erythematosus (SLE). A peptide is obtained, consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY [SEQ ID NO: 2] in which serine in position 9 is phosphorylated and methionine in position 3 is oxidized or of RIHMVYSKRSGKPRGYAFIEY [SEQ ID NO: 1], in which serine in position 10 is phosphorylated and methionine in position 4 is oxidized.EFFECT: invention provides peptide or salt thereof, effective in systemic lupus erythematosus treatment.8 cl, 6 dwg, 4 tbl, 4 ex
ethod for prevention and treatment of newborns calves diarrheal diseases // 2619859
FIELD: veterinary medicine.SUBSTANCE: method comprises oral applying of the complex with metabolic agents, immunomodulating and anti-infective effect of 100 ml 30 minutes prior to the drinking colostrum or milk twice a day for 5 days. The cure comprises succinic acid as metabolite, immunopotentiator - antiseptic-stimulator of Dorogov of second fraction (ASD-2) or levamisole, the antimicrobial component - iodinol in the following ratio: succinic acid - 1 g; antiseptic stimulator of Dorogov of second fraction (ASD-2) - 4 ml or levamisole - 0.05 g; iodinol - 30 ml; Boiled water - 100 ml.EFFECT: cure is highly effective for the prevention and treatment of diarrhea of newborn calves.7 tbl, ex 5

Immune modulators, preparations and compositions containing immune modulators, activity tests of immune modulators, preparations and compositions containing them, and methods // 2619555
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used to create an immune stimulating composition. The composition for immune function improvement, comprising: an immunomodulatory component containing an extract of at least one colostrum and eggs, including immune modulating molecules nanofraction with molecular weights from about 4000 Da to about 3000 Da. The group of inventions also relates to the method for immune system modulation and the method for preparation of a composition for immune function improvement. Application of this composition allows to maintain the balance of the cell-mediated immunity of the subject, enhancing the immune modulation of T-helper cells, memory T-cells and NK cells.EFFECT: group of inventions can improve body's immune function.24 cl, 4 dwg, 8 tbl
Bruton's tyrosine kinase inhibitors // 2619465
FIELD: pharmacology.SUBSTANCE: compounds can be used as therapeutically active substances for the treatment of inflammatory and/or autoimmune conditions selected from rheumatoid arthritis and asthma. In formula I A is phenyl, n is 1 or 2, R1 is CH2NHC(=O)R1' or CH2NHC(=O)CH2NHR1', where n is 1. And one R1 is halogen, and the other R1 represents CH2NHC(=O)R1' or CH2N(CH3)C(=O)R1', when n is 2. R1' represents a lower alkoxy group, phenyl, an unsaturated or partially unsaturated 8-9-membered bicyclic heterocycle containing 1-2 heteroatoms in the bicyclic system selected from nitrogen and sulfur, or a 4-6-membered monocyclic heteroaryl with 1-3 heteroatoms selected from nitrogen, oxygen and sulfur, or a 4-5-membered heterocycloalkyl containing oxygen or nitrogen atoms as heteroatoms, optionally substituted by one or more R1". Each radical R1" is an independent lower alkyl, halogen, 3-6-membered cycloalkyl, 4-membered heterocycloalkyl with an oxygen atom as a heteroatom, lower alkyl-4-membered heterocycloalkyl with an oxygen atom as a heteroatom, oxo group, cyano-lower alkyl, hydroxyl-lower alkyl or lower alkoxy group. R2 is H, R3 or R4. R3 represents C(=O)OR3', C(=O)R3' or C(=O)NH(CH2)2R3'. R3' is H, a lower alkyl, 6-membered heterocycloalkyl with 1-2 heteroatoms selected from nitrogen and oxygen, an amino group or OH. R4' is a pyrasolyl possibly substituted with R4'. And R4' is a methyl, CH2-CH2N(CH3)2, CH2C(=O)OCH2CH3, CH2C(=O)OH or CH2CH2OH.EFFECT: increased efficiency of treatment.18 cl, 2 tbl, 51 ex

edication for prevention and treatment of free radical pathology in animals // 2619342
FIELD: veterinary medicine.SUBSTANCE: medication for the prevention and treatment of Pathology findings in animals contains 3.0-5.0 mas.% of phenyl-tert-butilnitrona, 1.0-2.0 mas.% β-carotene, 7.5-10.5 mas.% 2.6-ditretbutil-4-nonylphenol, 10.0-15.0 mas.% of 2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo-(3,3,0)-oktadyselenon-3.7, 5.0-9.0 mas.% Solutol HS15, 0.2-0.4 mas.% Polyvinylpyrrolidone and water for injection (the rest).EFFECT: increasing the stress resistance of the organism, reducing toxicity and increased ease of use and dosage.dwg 6 7 ex
ethod of selecting the immunosuppression regime to children of early age in a remote period after transplantation of the liver // 2619216
FIELD: medicine.SUBSTANCE: one year after transplantation in blood serum, the content of insulin-like growth factor 1 (IGF-1) and soluble CD30 (sCD30) is determined in liver recipients, and the dose of tacrolimus is adjusted to the specific concentration of IGF-1 and sCD30, the daily dose of tacrolimus is determined by formula D=1.3764+0.0081×G-0.0026×C, where D is the daily dose of tacrolimus, mg; G - serum level of IGF-1, ng/ml; C - content of sCD30 in serum, ng/ml.EFFECT: use of this method allows for effective prevention of complications in young children after liver transplantation for congenital diseases of the hepatobiliary system in the long-term due to individual selection of tacrolimus concentration one year after liver transplantation.5 ex

Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response // 2619187
FIELD: biotechnology.SUBSTANCE: fusion protein having (a) a binding domain with AIC or a binding domain with a CD91 receptor located at the N-terminus of a fusion protein, (b) a translocation peptide of 34 to 112 amino acid residues located at the C-terminus of the binding domain with AIC or binding domain with the CD91 receptor; (c) a pathogen antigen; (d) a nuclear export signal and (e) a sequence providing retention in the endoplasmic reticulum located at the C-terminus of the fusion protein, where the nuclear export signal is between the antigen and the sequence providing retention in the endoplasmic reticulum, or between the translocation peptide and the antigen.EFFECT: proposed invention allows induction of enhanced antigen-specific T-cell responses against a pathogen selected from HPV, PRRSV, HIV-1, Dengue virus, HCV, HBV, PCV2, CSFV, FMDV, NDV, TGEV, PEDV, influenza virus, pseudorabies virus , parvovirus, SVDV, smallpox virus, rotavirus, Mycoplasma pneumonia, herpes virus, infectious bronchitis virus or infectious bursitis virus.20 cl, 8 dwg, 1 tbl, 8 ex
ethod for obtaining of biologically active substances in conium maculatum l cell culture // 2619182
FIELD: biotechnology.SUBSTANCE: invention is a method for biologically active substances preparation in Conium maculatum L cell culture, comprising Conium maculatum callus culture culturing on a nutrient medium MC in the presence of 6-benzylaminopurine for 30 days, biomass harvesting and selection of biologically active substances; the difference is that the cultivation is carried out at 26±1°C, 70% humidity, in the dark, 6-benzylaminopurine is introduced into the nutrient medium at a concentration of 1 to 0.1 mg/l together with 2.4-dichlorophenoxyacetic acid at a concentration in the range of 1 to 0.5 mg/l or together with α-naphthylacetic acid at a concentration in the range of 3 to 0.5 mg/l, and the biologically active substances are isolated by acidic and alkaline chloroform extraction.EFFECT: invention allows to obtain the required amount of callus culture biomass, containing BAV-furanocoumarins and acyclic triterpenoids.1 tbl

Human xcr1 antibodies // 2619180
FIELD: biotechnology.SUBSTANCE: invention refers to the field of biochemistry, in particular, to an antibody that specifically binds to human XCR1. Also the conjugate contains the specified antibody, pharmaceutical composition containing the specified antibody for the treatment of immune-associated diseases and nucleic acid coding the specified antibody are discovered. A way of treatment of immune-associated disease with the introduction of the specified antibody is discovered.EFFECT: invention allows effective treatment of immune-associated diseases.16 cl, 26 dwg, 15 tbl, 14 ex

Immunogenic compositions of multiple antigen presentation, methods and applications relating thereto // 2619176
FIELD: biotechnology.SUBSTANCE: immunogenic composition against one or more polysaccharide antigen, peptide antigen or polypeptide antigen comprises at least one antigenic polysaccharide, at least one peptide or polypeptide antigen and at least one complementary affinity molecules pair. At that, the first affinity molecule is associated with at least one antigenic polysaccharide, and the complementary affinity molecule is associated with at least one peptide or polypeptide antigen, wherein the said first affinity molecule binds to the complementary affinity molecule for the compound of peptide or polypeptide antigen and a polysaccharide antigen.EFFECT: invention allows to induce both humoral and cellular immune responses to one or multiple antigens simultaneously.20 cl, 40 dwg, 4 tbl, 4 ex

Crystalline solvates of hydrochloride 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one // 2619129
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, in particular to crystalline dihydrate 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one of formula and a solid pharmaceutical composition thereof.EFFECT: obtained crystalline hydrochloride dihydrate, having better stability and hygroscopicity, which is preferable in obtaining the medicinal product based on it.16 cl, 14 dwg, 1 tbl

Derivatives of pyrrolopyrimidine useful as jak-kinases inhibitors // 2618673
FIELD: chemistry.SUBSTANCE: invention relates to a heterocyclic compound of the formula (I) or to its enantiomer, a diastereomer and a mixture thereof and a pharmaceutically acceptable salt thereof, wherein A: CH or N; L: bond or C1-2alkyl; R1 is selected from hydrogen, C1-4alkyl, heteroaryl, - (CH2)nC(O)OR15, -C(O)R15, -C(O)NR16R17, and -S(O)mR15, where each of alkyl or heteroaryl is possible is substituted with 1-3 groups selected from halogen, hydroxy, cyano, C1-2alkyl, C1-2alkoxy, C3cycloalkyl, C6aryl, pyridine and - (CH2)nC(O)OR15; R2 or R4 is independently selected from hydrogen and C1-2alkyl; R or R3 is independently selected from hydrogen and halogen; R5 or R6 is independently selected from hydrogen and C1-2alkyl; R7, R8, R9 or R10 is independently selected from hydrogen, C1-2alkyl and hydroxyC1-2alkyl; R11, R12, R13 or R14 is independently selected from hydrogen or R11 and R12 or R13 and R14 taken together form an oxo group; R15 is selected from C1-4alkyl, C3cycloalkyl, C2alkenyl, C6aryl and pyridine, wherein each of alkyl, cycloalkyl or heteroaryl is optionally substituted with 1 to 4 groups selected from halogen, hydroxy, cyano, C1-4alkoxy, C6aryl, tetrazole, -NR19R20, -S(O)mR18, -NHC(O)OR18 and -NHS(O)mR18; R16 or R17 is independently selected from hydrogen, C1-3alkyl and heteroaryl, wherein heteroaryl is optionally substituted by one selected from C1-2alkyl, hydroxy, C1-2alkoxy, C3cycloalkyl, hydroxyC1alkyl and-OR18; R18 is selected from C1-4alkyl and hydroxyC1-4alkyl; R19 or R20 is independently selected from the group consisting of hydrogen; M is 0, 1 or 2; N is 0 or 1; P is 0, 1 or 2; Q is 0 or 1; S is 1 or 2; And t is 1 or 2. The invention also relates to particular intermediates, a process for the preparation of a compound of formula (I), a pharmaceutical composition based on it, the use of a compound of formula (I), a method for inhibiting JAK kinases, and a method for treating certain diseases of the immune system.EFFECT: new heterocyclic compounds possessing the activity of JAK-kinase inhibitor have been obtained.22 cl, 7 tbl, 158 ex
Bruton's tyrosine kinase inhibitors // 2618529
FIELD: pharmacy.SUBSTANCE: invention relates to a compound of general formula I, below, or a pharmaceutically acceptable salt thereof. In the formula I compound, X is halogen; Y is H or lower alkyl; R is -R1-R2-R3; R1; R1 is pyridyl; R2 is -C (= O) or is absent; R3 is morpholinyl or pyrrolidinyl, optionally substituted by a lower alkyl. The above compounds are used to modulate OMB activity and treat diseases associated with excessive OMB activity. Furthermore, these compounds are used for treatment of inflammatory and autoimmune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. The invention also relates to the pharmaceutical composition comprising a compound of formula I and at least one carrier, diluent or excipient.EFFECT: increased efficiency of compounds application.20 cl, 2 tbl, 7 ex
ethod of treating and preventing chronic inflammatory diseases of nasopharynx associated with inhalation exposure to benzene and formaldehyde in children // 2618469
FIELD: medicine.SUBSTANCE: invention can be used to treat and prevent chronic inflammatory diseases of nasopharynx (CIDN) in children aged 4 through 10 years old, living in area of industrial enterprises impact in conditions of atmospheric air pollution with benzene and formaldehyde. Treatment is carried out by combined administration of the following medicinal products to children: "Tonsilgon N" preparation orally in a dose for children aged 4 through 6 years old - 10 drops 3-4 times a day; for children over 6 years - 1 pill 3-4 times a day, for 21 days course; "Multi-Tabs Junior" 1 tablet once a day for 21 days; "Eslidine" 1 capsule twice a day before meals in the morning and evening for 21 days; "Zodac" preparation 5 mg once a day in a dose for children aged 4 through 6 years old; 10 mg once a day for children over 6 years old, for 21 days course, and simultaneously with children medical treatment, starting from the third day of drug administration, pulsed low-frequency magnetotherapy is employed for 10 minutes daily or every other day for 10 days course on nose sinuses or submandibular regions in the form of two-inductor technique with transverse arrangement of inductors and feedback sensor position at right supraclavicular region.EFFECT: invention provides treatment and prevention of chronic inflammatory disease of nasopharynx associated with exposure to benzene and formaldehyde in children.5 cl, 5 tbl

ethod of reducing basophils number // 2618455
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for reduction of number of basophils in humans. For this patient gets approximately 0.03 mg/kg of monoclonal, chimeric, humanized or human antibody, which binds interleukin receptor IL-5R and includes Fc region of immunoglobulin, not containing fucose. Application of this antibody reduces number of basophils in peripheral blood in human circulatory system 24 hours after administration.EFFECT: application of given method enables to induce stable reduction of basophils by single intravenous dose of antibody.9 cl, 1 tbl, 14 ex, 31 dwg
ethod of increasing non-specific resistance and productivity of growing pigs in post-weaning period // 2618399
FIELD: veterinary medicine.SUBSTANCE: method involves growing animals under normal feeding and keeping conditions. Additionally, the lithium salt of oxyglycine is administered parenterally in an amount of 2 mg per 1 kg of body weight at the age of 1 and 2 months.EFFECT: increased non-specific resistance and productivity of animals.4 tbl, 1 ex
Phenylpyrrole derivative // 2618228
FIELD: pharmacy.SUBSTANCE: invention relates to new derivatives of formula (I) Q: (A) or (B) phenylpyrrole, or pharmaceutically acceptable salts thereof, which are useful for prevention or treatment of diseases such as dementia, Alzheimer's disease, attention deficit, hyperactivity disorder, schizophrenia, epilepsy, "central" cramp, obesity, diabetes, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behavior-induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm, parasomnia, sleep-related traffic violation, insomnia and depression, or allergic rhinitis.EFFECT: increased compound application effeciency.13 cl, 3 tbl, 10 ex
Derivatives of 5-substituted quinazolinone, compositions containing them and methods of application thereof // 2617989
FIELD: pharmaceutics.SUBSTANCE: compounds of formula (I) R1 is halogen atom; (C1-C6) alkyl, optionally substituted with one or more halogen atoms; (C1-C6) alkoxy group, optionally substituted with one or more halogen atoms, or -(CH2)nNHRa, where Ra represents hydrogen atom; -C(O)-(CH2)n-phenyl or -C(O)-(CH2)n-pyridyl, where phenyl is optionally substituted with one or more substitutes of halogen atom; -SCF3; (C1-C6)alkyl, optionally substituted with one or more halogen atoms, or (C1-C6)alkoxy group, optionally substituted with one or more halogen atoms; -C(O)-(C1-C8)alkyl, where alkyl is optionally substituted with one or more halogen atoms; -C(O)-(CH2)n-(C3-C10-cycloalkyl); -C(O)-(CH2)n-NRbRc, where Rb and Rc are hydrogen atoms independently of each other; (C1-C6)alkyl; or phenyl, optionally substituted with one or more substitutes of halogen atom or (C1-C6)alkyl; -C(O)-(CH2)n-O-(C1-C6)alkyl; or -C(O)-(CH2)n-O-(CH2)n-phenyl; R2 is hydrogen atom; OH; phenyl or (C1-C6) alkyl, optionally substituted with one or more halogen atoms; R3 is hydrogen atom; or (C1-C6) alkyl; and n takes values 0, 1 or 2.EFFECT: method is disclosed of treating or controlling diseases or disorders, such as cancer involving administering 5-substituted quinazoline compound of formula (I) or its pharmaceutically acceptable salt, solvate or stereoisomer.32 cl, 59 ex

Antibodies to human csf-1r and use thereof // 2617971
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody against human macrophage colony-stimulating factor 1 receptor (CSF-1R) is presented. Invention also relates to method of producing above antibody, pharmaceutical composition and use of above antibody.EFFECT: invention enables inhibiting binding of CSF-1 with CSF-1R and can be used for treating cancer, bone loss, inflammatory diseases, as well as for preventing or treating metastases.12 cl, 1 dwg, 7 tbl, 8 ex

Antibodies to human csf-1r and use thereof // 2617966
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody against human macrophage colony-stimulating factor 1 receptor (CSF-1R) is presented. Invention also relates to method of producing above antibody, pharmaceutical composition and use of above antibody.EFFECT: invention enables inhibiting binding of CSF-1 with CSF-1R and can be used for treating cancer, bone loss, inflammatory diseases, as well as for preventing or treating metastases.12 cl, 1 dwg, 7 tbl, 8 ex

Bispecific single-chain antibody to psmaxcd3 with interspecies specificity // 2617942
FIELD: biotechnology.SUBSTANCE: bispecific single-chain antibody molecule comprising the first binding domain capable of binding to an epitope of the CD3 (Epsilon)-chain of human and common marmoset (Callithrix jacchus), oedipus tamarins (Saguinis oedipus) or common squirrel monkey (Saimiri sciureus), wherein said epitope comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu (QDGNE) and a second binding domain capable of binding to a specific membrane antigen of human (PSMA) and cynomolgus monkey prostate, is proposed. Also are described nucleic acid encoding a bispecific single chain antibody molecule, a host cell and a method for producing the bispecific single chain antibody molecule of the invention. Also are considered a pharmaceutical composition for the prevention, treatment or amelioration of cancer associated with the expression of PSMA, and the application of the bispecific single chain antibody molecule for manufacturing of such pharmaceutical composition.EFFECT: invention may find further application in the treatment of diseases associated with the PSMA.16 cl, 2 dwg, 4 tbl, 3 ex

Preparations of antibodies // 2617532
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine. Antibody preparation is disclosed containing IgG, IgA and at least 5 % of IgM antibodies by weight of total amount of antibodies having specific activity of complement activation, wherein in in vitro analysis of antibody preparation it essentially does not form C5a and/or essentially does not form C3a. Use of antibody preparation for preparing medicinal agent for treating immunological disorders or bacterial infection and method of treating patient suffering from immunological disorder or bacterial infection are disclosed.EFFECT: presented group of inventions provides effective agents and methods of complement activation.28 cl, 3 dwg, 13 tbl, 11 ex

Pharmaceutical composition containing complex of polymer carrier and carried substance and at least one protein or peptide antigen // 2617058
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns pharmaceutical composition for vaccination against infection, allergy or allergic disease, autoimmune disease or cancer or tumors, contains complex of polymer carrier and carried substance, at least one protein or peptide antigen. Group of inventions also concerns kit for vaccination against infection, allergy or allergic disease, autoimmune disease or cancer or tumors; use of said pharmaceutical composition as vaccine.EFFECT: group of inventions provides increased immune response to peptide or protein.13 cl, 16 ex, 30 dwg, 1 tbl
orpholino-substituted derivatives of urea or carbamate as mtor inhibitors // 2616619
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula (I) , where m equals 1 or 2; n equals 0, 1 or 2; each of R1 is independenly selected from the group consisting of C1-6alkyl, where C1-6alkyl is probably substitued with one R3; probably, two R1 are joint with a ring to which they are attached to form 8-membered heterobicycle; R3 is OR4; R4 is H; T0 is phenyl where T0 is substituted with the group N (R5a) C(O) N (R5bR5); R5a, R5b are independently selected from the group consisting of H; R5 is T2 or C1-6alkyl, where C1-6alkyl is probably substituted with 1-4 R8, which are the same or different; R8 is halogen; OR9; N (R9R9a); R9, R9a are independently selected from the group consisting of H; T2 is C3-7cycloalkyl; 4-6-membered heterocyclyl, wherein 1 circular atom is substituted with oxygen heteroatom; 6-membered aromatic heterocyclyl, wherein 1 circular atom is substituted with nitrogen heteroatom; and phenyl, wherein T2 is probably substituted with one or two R10, which are the same or different; R10 is halogen; OR11; or C1-6alkyl, where C1-6alkyl is probably substituted with one R12; R11 is H; R12 is OR13; R13 is H; T1 is phenyl or 6-membered aromatic heterocycle, wherein 1 carbon atom is substituted with nitrogen heteroatom, wherein T1 is substituted with a group S(O)2R14 and is probably additionally substituted with one R15; R15 is halogen; R14 is C1-6alkyl or unsubstituted 5-membered heterocyclyl ring, wherein 1 circular atom is substituted with nitrogen heteroatom. Compounds of formula (I) possess mTOR inhibitory activity. The invention also relates to a pharmaceutical composition, to compound application for drug manufacture and to a treatment method.EFFECT: new compounds of formula are obtained, which are useful for treatment or prevention of mTOR-related diseases and disorders.21 cl, 6 tbl, 44 ex
 
2551040.
Up!